Actuate Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Actuate Therapeutics, Inc. (ACTU) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Actuate Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.34M, a 15.10% decline year-over-year.
- Actuate Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.36M, a 20.56% increase year-over-year.
- Actuate Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.80M, a 218.14% increase year-over-year.
- Actuate Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.58M, a 1654.38% increase year-over-year.
- Actuate Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.05M, a 202.97% increase from fiscal 2024.
- Actuate Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.00M, a 371.22% increase from fiscal 2023.
- Actuate Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $423.54K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.34M 10-Q · filed 2026-08-14 | $2.70M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $1.36M 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $6.05M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $1.80M 10-Q · filed 2025-11-13 | $3.38M derived: sum of 2 quarters · filed 2026-08-14 | $4.50M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $1.58M 10-Q · filed 2026-08-14 | $2.70M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $1.13M 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $2.00M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $565.98K 10-Q · filed 2025-11-13 | $656.00K derived: sum of 2 quarters · filed 2025-11-13 | $804.21K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $90.02K 10-Q · filed 2025-11-13 | $238.22K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $148.21K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $423.54K 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $155.23K 10-Q · filed 2024-11-13 | $228.36K derived: sum of 2 quarters · filed 2024-11-13 | $301.49K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $73.13K 10-Q · filed 2024-11-13 | $146.26K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $73.13K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |